Fixed Dose MMF vs Concentration Controlled MMF After Renal Transplantation

Inclusion Criteria: * Renal transplant recipients who have completed their second birthday, * Recipients from living (related or unrelated), cadaveric (non-heart beating or heart beating) donors, * Single organ recipient (kidney only), * Women of childbearing potential should have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/ml within 1 week prior to beginning MMF treatment. Effective contraception must be used before beginning therapy, during therapy and for 6 weeks following discontinuation of therapy, even where there has been a history of infertility, unless due to hysterectomy, * Patients or patient's parent/guardian providing written informed consent, * Patients co-operative and able to complete all the assessment procedures. Exclusion Criteria: * Patients receiving immunosuppressive therapy (except steroid treatment) within the preceding 28 days, except that immunosuppressive medication may be initiated up to 48 hours before transplantation. Furthermore, all patients should receive 1 g \[adults\] or 600 mg/m2 \[paediatric patients\] of MMF therapy within 6 hours prior to transplantation, * PRA \> 50% within 6 months prior to enrolment, * Cold ischaemia time \>48 hours, * History of malignancy (except localised non-melanotic skin cancer) or the presence of any active malignancy at the time of transplant, * Active peptic ulcer disease, * Active infection, * Mandatory intake of prohibited drugs or it is probable that the patient will require treatment with such drugs after transplant, * Pregnant or lactating females, * Women of child-bearing potential not willing to use a reliable form of contraception, * Patient is allergic or intolerant to polysorbate 80 (TWEEN), phenylalanine (aspartame), steroids, MMF, MPA, tacrolimus or cyclosporin, * Patient or donor with positive tests for HIV or hepatitis B surface antigen, * Patients with liver cirrhosis or clinical evidence of portal hypertension or other indication of moderate or severe liver disease. (Note: it is strongly recommended that patients with hepatitis C have a liver biopsy performed prior to transplantation), * Incompatible ABO blood type and/or positive crossmatch, * Patient has any form of substance abuse, psychiatric disorder or condition, which, in the opinion of the investigator, may invalidate communication with the investigator or with study procedures, * Patients whose laboratory results reveal severe anaemia (as defined by a haemoglobin value \<6 mmol/L \[9.7 g/dL\] for adults receiving erythropoietin, \<4.1 mmol/L \[6.6 g/dL\] for paediatric patients \[regardless of erythropoietin treatment\]), leukopenia (as defined by a WBC value of \<2500/mm3) or thrombocytopenia (as defined by a platelet count of \<75,000/mm3).